Fadi Braiteh
University of Nevada, Las Vegas · 195 works · 9,848 citations · h-index 37
Top works
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- Successful treatment of Erdheim-Chester disease, a non–Langerhans-cell histiocytosis, with interferon-α
- Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
- Characteristics, Findings, and Outcomes of Palliative Care Inpatient Consultations at a Comprehensive Cancer Center
- Predictors of Access to Palliative Care Services among Patients Who Died at a Comprehensive Cancer Center
- Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial
- Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
- Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
- Cryptogenic invasive Klebsiella pneumoniae liver abscess syndrome
- Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer
- Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
- Uncommon tumors and exceptional therapies: paradox or paradigm?
- Phase I Study of Epigenetic Modulation with 5-Azacytidine and Valproic Acid in Patients with Advanced Cancers
- Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- 14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)
- Long‐term effects of crizotinib in ALK‐positive tumors (excluding NSCLC): A phase 1b open‐label study